DIVISION of CARDIOLOGY - Summary of WEEKLY ROUNDS SCHEDULE

DIVISION OF CARDIOLOGY - summary OF WEEKLY ROUNDS SCHEDULE

MONDAY, JANUARY 25 to FRIDAY, JANUARY 29, 2016

Monday, January 25:

8:00-9:00 / Aud B UH,
B2-116 VH &
B2-075
St. Joseph’s
OTN Event #
50409627 / Cardiovascular Grand Rounds Presenter: G. Klein
Title of Presentation: TBA
12:00-1:30 / B6-115 UH
OTN Event #
50897024 / Adult Congenital Cardiac Surgery Rounds - Videoconference from Toronto
Cases & Learning Objectives:
Case 1 – Dr. Roche Dx: Repaired coarctation with left subclavian flap. Bicuspid aortic valve post balloon valvotomy. Severe aortic regurgitation. Mildly dilated proximal ascending aorta. To review cath and MRI. Surgical referral.
Case 2 – Dr. Wald Dx: Pulmonary atresia with ventricular septal defect post conduit (right ventricle to pulmonary artery). Severe RV-PA conduit regurgitation. Moderate right ventricular dilatation. Accessory LAD from the RCA not crossing the RVOT. Residual ventricular septal defects. DiGeorge syndrome. Mild aortic root and ascending aortic dilatation. To review cath, echo, MRI and CP study. Surgical referral.
Case 3 – Dr. Silversides Dx: TOF. RVOT obstruction. PR. Dilated RV To review echo, MRI and CP study. Surgical/Interventional referral.
Case 4 – Dr. Wald Dx: Ebstein anomaly of the tricuspid valve and ASD. Percutaneous ASD closure in 2002. Severe tricuspid regurgitation, severely enlarged functional right ventricle with mild-moderate global systolic dysfunction. Asymptomatic. To review echo, TEE, MRI, EST and CP study. Management planning.
Case 5 – Dr. Oechslin Dx: Marfan syndrome with prior endocarditis and aortic root + bioprosthetic AVR/MVR. Severe bioprosthetic aortic stenosis with decrease EF. To review cath, echo, MRI and EST. Surgical referral.

Tuesday, January 26:

7:00-8:00 / B6-115 UH
OTN Event #
51365027 / Complex Revascularization Rounds Presenters: CV Surgeons & Interventional Cardiologists
Faculty Supervisors: D. Nagpal & P. Garg
Case-based presentation and discussion
Learning Objectives:
1. To develop a systematic approach to interpretation of coronary angiograms.
2. To discuss interesting case examples and their management.
3. To apply an evidence-based approach to complex revascularization cases in order to improve outcomes.
2:00-5:00 / B6-128 UH / DIDACTIC EDUCATION SESSIONS:
2:00-5:00 / B6-128 UH / COMMUNICATIONS SEMINAR
Presenter: S. Koivu Topic: Difficult Conversations

Wednesday, January 27:

8:00-9:00 / B6-115 UH
OTN Event #
50200947 / EP Rounds: Technology Rounds Presenters: Attendings & Fellows
Learning Objectives:
1. To review technological advances in EP.
2. To provide an overview of the principles behind the technology.
3. To review the clinical uses of the technology.
12:00-1:00 / B6-115 UH &
C2-504 VH
OTN Event #
46453529 / Adult Congenital Cardiac Teaching Rounds - Videoconference from Toronto
Presenter: L. Mertens
Title of Presentation: Right Ventricular Functions

Thursday, January 28:

8:00-9:00 / B6-128 UH / Graphics Rounds: Chronic MI Presenter: J. Brown

Friday, January 29:

8:00-9:00 / B6-128 UH / EP Tracing Rounds: Case Presentations with ECG and Intra-cardiac tracings
Presenters: Attendings Fellows
Learning Objectives:
1. To develop a systematic approach to EP tracings.
2. To discuss interesting case examples.
3. To review electrophysiology principles and concepts.

Some of these educational activities/rounds are an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of The Royal College of Physicians and Surgeons of Canada, approved by the Division of Cardiology Education Committee - Western University.

Supported by unrestricted grants-in-aid provided by:

Aegerion Pharmaceuticals (Juxtapid (lomitapide)), Amgen Canada Inc. (Repatha), AstraZeneca Canada Inc. (Brilinta (Ticagrelor)),

Bayer HealthCare Pharmaceuticals (XARELTO® rivaroxaban tablet), Boehringer Ingelheim (Canada) Ltd. (Pradax (dabigatran), Twynsta (telmisartan/amlodipine)), Bristol-Myers Squibb Canada & Pfizer Canada Inc., (Eliquis (apixaban)), Medtronic of Canada Inc., Merck (Ezetrol, Olmetec®), Novartis Pharmaceuticals of Canada Inc. (Entresto), Servier Canada Inc. (Coversyl)